Mumbai, May 11 (Udaipur Kiran): Biocon is currently trading at Rs. 393.25, up by 12.70 points or 3.34% from its previous closing of Rs. 380.55 on the BSE.
The scrip opened at Rs. 348.05 and has touched a high and low of Rs. 396.00 and Rs. 348.05 respectively. So far 501960 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 317.90 on 12-May-2025.
Last one week high and low of the scrip stood at Rs. 396.45 and Rs. 338.00 respectively. The current market cap of the company is Rs. 63734.09 crore.
The promoters holding in the company stood at 44.91%, while Institutions and Non-Institutions held 31.59% and 23.49% respectively.
Biocon’s subsidiary — Biocon Pharma has secured approval from Health Canada for Micafungin for injection, USP, 50 mg and 100 mg. The approved product is indicated for use in adults and children four months and older for treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections; treatment of patients with esophageal candidiasis; and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. The approval will further strengthen the company’s integrated biosimilars and generics portfolio.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
